Final Programme

Scientific Programme Monday, April 3, 2006
Meet-the-Expert Sessions
Méditerranée 2 Recent treatment issues in tuberculosis
E189 and non-tuberculosis mycobacteria
07:15– Experts: Richard Wallace (Tyler, US)
08:15– Bertrand Dautzenberg (Paris, FR)
Objectives:
– to be familiar with recently revised American
Thoracic Society recommendation for
treatment of M. avium complex (MAC) lung
disease, including a three-times-weekly
regimen
– to appreciate the limitations of susceptibility
testing for non-tuberculosis mycobacteria,
especially for MAC
– to be knowledgeable of current accepted
treatment regimens for PPD positive individuals
(converters or high risk individuals),
including those who are HIV positive
Méditerranée 3 The role of epidemiology and typing
E190 in outbreak investigation
07:15– Experts: Panayotis T. Tassios (Athens, GR)
08:15– Jean-Claude Desenclos (Saint-Maurice, FR)
Objectives:
– to describe the distinct but complementary
contributions of epidemiology and typing
– to assess different examples of outbreak
investigations, e.g.: common source vs.
person-to-person, community- vs. hospitalacquired
– to demonstrate the need for continuous
feedback between epidemiology and typing
at different stages of an investigation
Iris How to interpret laboratory test results?
E191 Experts: George Schmid (Geneva, WHO)
07:15– Achim Schwenk (London, UK)
08:15–
Objectives:
– to interpret sensitivity, specificity, and
predictive values of laboratory tests in
clinical practice
– to understand how knowing the process of
determining cut-off values for separating
positive from negative tests results can
influence clinical practice
– to understand the concepts of pre-test and
post-test probability
– to understand the concept of numbersneeded-to-test
Hermes Minimal requirements for an effective
E192 infection control surveillance
07:15– Experts: Andreas Widmer (Basel, CH)
08:15– Marc Bonten (Utrecht, NL)
Objectives:
– to provide an overview of different
surveillance systems
– to establish sensitivity and specificity of
systems in comparison to workload
– to show principles and examples of computer
support for surveillance
– to examine practical issues:
incidence vs. prevalence, pitfalls
Clio Beta-lactamases: from bench to bedside
E193 Experts: Patrice Nordmann (Paris, FR)
07:15– Yehuda Carmeli (Tel Aviv, IL)
08:15–
Objectives:
– to identify the main broad-spectrum betalactamase-mediated
resistance phenotypes
in Gram-negative rods
– to know the spread and distribution of the
expanded-spectrum beta-lactamases in
Gram-negative rods worldwide
– to discuss the therapeutic alternatives for
treating infected patients
Erato Clinical trials and clinical practice
E194 Experts: Ben de Pauw (Nijmegen, NL)
07:15– David Denning (Manchester, UK)
08:15–
Objectives:
– to identify pitfalls in clinical trial on antifungal
agents, such as inclusion and exclusion
criteria, endpoints and others
– to translate trial data for use in treatment of
invasive fungal infections
– to discuss the relevance of meta-analysis
statistics
www.escmid.org/eccmid2006 page 47